LIVIVO - Search results -

Search results

Result 1 - 10 of total 26

Search options

Article ; Online: Interactions of ST-elevation myocardial infarction, age, and sex and the risk of major adverse cardiovascular events among Chinese adults: a secondary analysis of a single-centre prospective cohort.

Wang, Cuiping / Zhou, Lin / Liang, Yi / Liu, Peijing / Yuan, Wei

2022 Volume 12, Issue 7, Page(s) e058494

Abstract: Objectives: This study aimed to evaluate the interactions of ST-elevation myocardial infarction (STEMI), ageing and sex with respect to the incidence of major adverse cardiovascular events (MACE) among Chinese adults.: Design: Secondary analysis of a ...

Abstract	Objectives: This study aimed to evaluate the interactions of ST-elevation myocardial infarction (STEMI), ageing and sex with respect to the incidence of major adverse cardiovascular events (MACE) among Chinese adults. Design: Secondary analysis of a single-centre prospective cohort. Setting: Patients who were admitted to cardiology clinics of the Affiliated Hospital of Jiangsu University due to acute myocardial infarction (MI) from June 2017 to November 2019 were eligible for inclusion in the study. This research only examined in-hospital cases. Participants: Patients aged <18 years or confirmed dead within 24 hours from admission were excluded. A total of 843 adults were included in the analysis. Primary and secondary outcome measures: MACE was defined as any occurrence of cardiovascular mortality, MI recurrence, cardiogenic shock or heart failure. The relative excess risk due to interaction (RERI), attributable proportion (AP) and the synergy index were computed to quantify the interactions. Men without STEMI and adults without STEMI aged <60 years were the reference groups when examining the risk of MACE. Results: The female participants with STEMI showed a statistically higher risk of MACE compared with the male participants without STEMI (relative risk (RR): 2.713, CI: 1.350 to 5.426, p=0.005). A 3.327 times higher risk of MACE was detected in the older adults with STEMI (aged ≥60 years) compared with the adults without STEMI aged <60 years (RR: 3.327, CI: 1.414 to 8.955, p=0.01). Older female patients also had an increased risk of MACE (RR: 3.033, CI: 1.432 to 6.777, p=0.005). A positive additive interaction was detected between STEMI and age (RERI: 1.917, CI: 0.196 to 3.637; AP: 0.576, CI: 0.174 to 0.979). STEMI and sex also indicated an additive interaction (AP: 0.459, CI: 0.018 to 0.899). Conclusion: In this Chinese population with MI, the risk of MACE was increased by about 2.7 times in women with STEMI compared with men without STEMI. MACE incidence increased by about 3.3 times in older patients with STEMI compared with younger patients without STEMI. STEMI and age, and STEMI and sex, may have a positive additive interaction.
MeSH term(s)	Aged ; China/epidemiology ; Female ; Heart ; Humans ; Male ; Myocardial Infarction/epidemiology ; Prospective Studies ; ST Elevation Myocardial Infarction/complications
Language	English
Publishing date	2022-07-12
Publishing country	England
Document type	Journal Article ; Research Support, Non-U.S. Gov't
ZDB-ID	2599832-8
ISSN	2044-6055 ; 2044-6055
ISSN (online)	2044-6055
ISSN	2044-6055
DOI	10.1136/bmjopen-2021-058494
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

Article ; Online: Retraction notice to Docosahexaenoic acid attenuates hypoxic pulmonary vasoconstriction by activating the large conductance Ca2+-activated K+ currents in pulmonary artery smooth muscle cells [Pulm. Pharmacol. Therap., 28/1 (2013) 9-16].

Yan, Jinchuan / Chen, Rui / Liu, Peijing / Gu, Yuchun

Pulmonary pharmacology & therapeutics

2021 Volume 69, Page(s) 101967

Language	English
Publishing date	2021-06-25
Publishing country	England
Document type	Journal Article ; Retraction of Publication
ZDB-ID	1399707-5
ISSN	1522-9629 ; 1094-5539
ISSN (online)	1522-9629
ISSN	1094-5539
DOI	10.1016/j.pupt.2020.101967
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 2389: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: A Case of Transcatheter Aortic Valve Replacement for the Treatment of Severe Aortic Stenosis with Multiple Organ Dysfunction.

Ma, Jinyu / Wang, Lunping / Chen, Rui / Yan, Jinchuan / Liang, Yi / Liu, Peijing

International heart journal

2020 Volume 61, Issue 2, Page(s) 390–396

Abstract: A 77-year-old woman with extremely high risk of mortality due to severe aortic stenosis (AS) and multiple organ failure was admitted to the affiliated hospital of Jiangsu University. She did not receive regular treatment since being diagnosed with AS 17 ... ...

Abstract	A 77-year-old woman with extremely high risk of mortality due to severe aortic stenosis (AS) and multiple organ failure was admitted to the affiliated hospital of Jiangsu University. She did not receive regular treatment since being diagnosed with AS 17 months previously. Frequent breakout of acute left heart failure after admission, with a low ostium of the left coronary artery showed by computed tomography, the patient underwent transcatheter aortic valve replacement (TAVR). Though cardiac conduction system abnormalities and a short-term elevation of pulmonary arterial pressure occurred in this patient after TAVR, she eventually recovered and her quality of life improved significantly. As the population adapted to TAVR keeps expanding, we believe this operation will play a more important role in the treatment of AS patients.
MeSH term(s)	Aged ; Aortic Valve Stenosis/complications ; Aortic Valve Stenosis/surgery ; Female ; Humans ; Multiple Organ Failure/complications ; Transcatheter Aortic Valve Replacement
Language	English
Publishing date	2020-03-04
Publishing country	Japan
Document type	Case Reports ; Journal Article
ZDB-ID	2187806-7
ISSN	1349-3299 ; 1349-2365
ISSN (online)	1349-3299
ISSN	1349-2365
DOI	10.1536/ihj.19-344
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 211: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Icosapent ethyl therapy for very high triglyceride levels: a 12-week, multi-center, placebo-controlled, randomized, double-blinded, phase III clinical trial in China.

Wang, Zhen / Zhang, Xin / Qu, Yanling / Zhang, Shuyang / Chen, Yundai / Chen, Xiaoping / Qi, Xin / Liu, Peijing / Liu, Shuqin / Jiang, Shan / Man, Ronghai / He, Liping / Wu, Ling / Li, Zhanquan / Shang, Yijun / Qiu, Zhaohui / Liu, Feng / Xu, Chenhong / Lai, Chunlin /

Ge, Junbo

Lipids in health and disease

2023 Volume 22, Issue 1, Page(s) 71

Abstract: Objectives: Eicosapentaenoic acid in its ethyl ester form is the single active component of icosapent ethyl (IPE). This study was a phase III, multi-center trial assessing the safety and efficiency of IPE for treating very high triglyceride (TG) in a ... ...

Abstract	Objectives: Eicosapentaenoic acid in its ethyl ester form is the single active component of icosapent ethyl (IPE). This study was a phase III, multi-center trial assessing the safety and efficiency of IPE for treating very high triglyceride (TG) in a Chinese cohort. Methods: Patients having TG levels (5.6-22.6 mmol/L) were enrolled and randomly assigned to receive a treatment of oral intake of 4 g or 2 g/day of IPE, or placebo. Before and after 12 weeks of treatment, TG levels were assessed and the median was calculated to determine the change between the baseline and week 12. In addition to examining TG levels, the impact of such treatments on other lipid changes was also investigated. The official Drug Clinical Trial Information Management Platform has registered this study (CTR20170362). Results: Random assignments were performed on 373 patients (mean age 48.9 years; 75.1% male). IPE (4 g/day) lowered TG levels by an average of 28.4% from baseline and by an average of 19.9% after correction for placebo (95% CI: 29.8%-10.0%, P < 0.001). In addition, plasma concentration of non-high-density lipoprotein cholesterol (non-HDL-C), very low-density lipoprotein (VLDL) cholesterol, and VLDL-TG remarkedly reduced after IPE (4 g/day) treatment by a median of 14.6%, 27.9%, and 25.2%, respectively compared with participants in placebo group. Compared to the placebo, neither 4 nor 2 g of IPE daily elevated LDL-C levels with statistical significance. IPE was well tolerated by all the treatment groups. Conclusions: IPE at 4 g/day dramatically lowered other atherogenic lipids without a noticeable increase in LDL-C, thereby decreasing TG levels in an exceptionally high-TG Chinese population.
MeSH term(s)	Humans ; Male ; Middle Aged ; Female ; Eicosapentaenoic Acid/therapeutic use ; Cholesterol, LDL ; Treatment Outcome ; Hypertriglyceridemia/drug therapy ; Triglycerides ; Cholesterol, VLDL ; Double-Blind Method ; Hydroxymethylglutaryl-CoA Reductase Inhibitors/therapeutic use
Chemical Substances	eicosapentaenoic acid ethyl ester (6GC8A4PAYH) ; Eicosapentaenoic Acid (AAN7QOV9EA) ; Cholesterol, LDL ; Triglycerides ; Cholesterol, VLDL ; Hydroxymethylglutaryl-CoA Reductase Inhibitors
Language	English
Publishing date	2023-06-10
Publishing country	England
Document type	Randomized Controlled Trial ; Multicenter Study ; Clinical Trial, Phase III ; Journal Article
ZDB-ID	2091381-3
ISSN	1476-511X ; 1476-511X
ISSN (online)	1476-511X
ISSN	1476-511X
DOI	10.1186/s12944-023-01838-8
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: Plasminogen activator inhibitor links obesity and thrombotic cerebrovascular diseases: The roles of PAI-1 and obesity on stroke.

Chen, Rui / Yan, Jinchuan / Liu, Peijing / Wang, Zhongqun / Wang, Cuiping

Metabolic brain disease

2017 Volume 32, Issue 3, Page(s) 667–673

Abstract: One of the global socioeconomic phenomena occurred during the last decades is the increased prevalence of obesity, with direct consequence on the risk of developing thrombotic disorders. As the physiological inhibitor of tissue plasminogen activator (tPA) ...

Abstract	One of the global socioeconomic phenomena occurred during the last decades is the increased prevalence of obesity, with direct consequence on the risk of developing thrombotic disorders. As the physiological inhibitor of tissue plasminogen activator (tPA) and urokinase plasminogen activator (uPA), plasminogen activator inhibitor-1 (PAI-1) is well known for its role in fibrinolysis. More and more evidences have shown that PAI-1 involves in physiopathologic mechanisms of many diseases and metabolic disorder. Increased serum level of PAI-1 has been observed in obesity and it also contributes to the development of adipose tissue and then has effects on obesity. Meantime, obesity affects also the PAI-1 levels. These evidences indicate the complicated interaction between PAI-1 and obesity. Many clinic studies have confirmed that obesity relates to the stroke outcome although there are many contradictory results. Simultaneously, correlation is found between plasma PAI-1 and thrombotic cerebrovascular diseases. This article reviews contemporary knowledge regarding the complex interplay of obesity, PAI-1 and stroke.
MeSH term(s)	Adipose Tissue/metabolism ; Animals ; Cerebrovascular Disorders/diagnosis ; Cerebrovascular Disorders/epidemiology ; Cerebrovascular Disorders/metabolism ; Humans ; Intracranial Thrombosis/diagnosis ; Intracranial Thrombosis/epidemiology ; Intracranial Thrombosis/metabolism ; Obesity/diagnosis ; Obesity/epidemiology ; Obesity/metabolism ; Plasminogen Activator Inhibitor 1/metabolism ; Stroke/diagnosis ; Stroke/epidemiology ; Stroke/metabolism
Chemical Substances	Plasminogen Activator Inhibitor 1 ; SERPINE1 protein, human
Language	English
Publishing date	2017-04-04
Publishing country	United States
Document type	Journal Article ; Review ; Research Support, Non-U.S. Gov't
ZDB-ID	632824-6
ISSN	1573-7365 ; 0885-7490
ISSN (online)	1573-7365
ISSN	0885-7490
DOI	10.1007/s11011-017-0007-3
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 2155: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

Article ; Online: Effects of thiazolidinedione therapy on inflammatory markers of type 2 diabetes: a meta-analysis of randomized controlled trials.

Chen, Rui / Yan, Jinchuan / Liu, Peijing / Wang, Zhongqun

PloS one

2015 Volume 10, Issue 4, Page(s) e0123703

Abstract: Background: Inflammation is a common feature in patients with type 2 diabetes mellitus (T2DM). This meta-analysis aimed to assess the influence of thiazolidinedione (TZD) therapy on the circulating levels of inflammatory markers in patients with T2DM.!## ...

Abstract	Background: Inflammation is a common feature in patients with type 2 diabetes mellitus (T2DM). This meta-analysis aimed to assess the influence of thiazolidinedione (TZD) therapy on the circulating levels of inflammatory markers in patients with T2DM. Methods and results: We searched the databases Medline, Embase, ScienceDirect, Web of Science, SpringerLink, and the Cochrane Library for randomized controlled trials (RCTs) that examined the effects of thiazolidinedione vs. a placebo on patients with T2DM. The main outcomes were absolute changes in levels of circulating inflammatory markers. Twenty-seven RCTs were included and data were analyzed using a fixed-effect model or a random-effect model based on heterogeneity. Pooled results indicated that circulating levels of high-sensitivity C reactive protein (hsCRP; SMD = -0.65, 95% CI = -0.98 to -0.32, p < 0.01), monocyte chemoattractant protein-1 (MCP-1; WMD = -54.19, 95% CI = -73.86 to -34.52, p < 0.01), von Willebrand factor% (vWF%; WMD = -8.18, 95% CI = -13.54 to -2.81, p 0.01), fibrinogen (SMD = -0.26, 95% CI = -0.41 to -0.11, p < 0.01) and E-selectin(WMD = -3.57, 95% CI = -5.59 to -1.54, p <0.01) were significantly decreased after TZD therapy. However, interleukin-6 (IL-6), matrix metalloproteinase-9 (MMP-9), soluble CD40 ligand, plasminogen activator inhibitor 1 (PAI-1) and intercellular adhesion molecule (ICAM-1) were not significantly affected. Subgroup analyses of PAI-1, vWF% and fibrinogen in terms of trial drugs showed significant reductions for rosiglitazone (all p valuses< 0.05), but not pioglitazone treatment. Conversely, the E-selectin (p < 0.01) lowering effect only existed in the pioglitazone group. Further, rosiglitazone and pioglitazone treatment reduced serum hsCRP and MCP-1 but had no marked effects on MMP-9, IL-6 and ICAM-1. Conclusions: Limited evidence suggested that TZD therapy had anti-inflammatory property that might contribute to its beneficial effect on inflammatory state in patients with type 2 diabetes.
MeSH term(s)	Biomarkers/blood ; Diabetes Mellitus, Type 2/blood ; Diabetes Mellitus, Type 2/drug therapy ; Diabetes Mellitus, Type 2/immunology ; Humans ; Hypoglycemic Agents/pharmacology ; Hypoglycemic Agents/therapeutic use ; Inflammation Mediators/blood ; Randomized Controlled Trials as Topic ; Thiazolidinediones/pharmacology ; Thiazolidinediones/therapeutic use ; Treatment Outcome
Chemical Substances	Biomarkers ; Hypoglycemic Agents ; Inflammation Mediators ; Thiazolidinediones ; 2,4-thiazolidinedione (AA68LXK93C)
Language	English
Publishing date	2015-04-21
Publishing country	United States
Document type	Journal Article ; Meta-Analysis ; Research Support, Non-U.S. Gov't
ZDB-ID	2267670-3
ISSN	1932-6203 ; 1932-6203
ISSN (online)	1932-6203
ISSN	1932-6203
DOI	10.1371/journal.pone.0123703
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article: Anti-Diabetic and Anti-Nephritic Activities of Grifola frondosa Mycelium Polysaccharides in Diet-Streptozotocin-Induced Diabetic Rats Via Modulation on Oxidative Stress

Kou, Ling / Du, Mingzhao / Liu, Peijing / Shang, Mengyuan / Wang, Xiaodong / Yang, Ping / Zhang, Baohai / Zhang, Yizhi

Applied biochemistry and biotechnology. 2019 Jan., v. 187, no. 1

2019

Abstract: Grifola frondosa is an edible fungus with a variety of potential pharmacological activities. This study investigates the hypoglycemic, anti-diabetic nephritic, and antioxidant properties of G. frondosa polysaccharides in diet-streptozotocin-induced ... ...

Abstract	Grifola frondosa is an edible fungus with a variety of potential pharmacological activities. This study investigates the hypoglycemic, anti-diabetic nephritic, and antioxidant properties of G. frondosa polysaccharides in diet-streptozotocin-induced diabetic rats. After a 4-week treatment with 100 mg/kg of metformin and 200 mg/kg of one of four different G. frondosa polysaccharide mixtures (especially GFPS3 and GFPS4), diabetic rats had enhanced body weight and suppressed plasma glucose, indicating the hypoglycemic activities of the G. frondosa polysaccharides. G. frondosa polysaccharides regulated the level of serum creatinine, blood urea nitrogen, N-acetyl-β-D-glucosaminidase, and albuminuria; inhibited the serum levels of interleukin (IL)-2, IL-6, and TNF-α; and enhanced the serum levels of matrix metalloproteinase 9 and interferon-α, confirming their anti-diabetic nephritic activities. G. frondosa polysaccharides ameliorated the pathological alterations in the kidneys of diabetic rats. Moreover, G. frondosa polysaccharides modulated the serum levels of oxidant factors such as superoxide dismutase, glutathione peroxidase, catalase, malondialdehyde, and reactive oxygen species, revealing their antioxidant properties. Furthermore, the administration of G. frondosa polysaccharides inhibited nuclear factor kappa B activities in the serum and kidneys. All of the data revealed that the activation of nuclear factor kappa B plays a central role in G. frondosa polysaccharide-mediated anti-diabetic and anti-nephritic activities.
Keywords	albuminuria ; animal disease models ; antioxidant activity ; beta-N-acetylhexosaminidase ; blood glucose ; blood serum ; body weight ; catalase ; creatinine ; diabetes ; edible fungi ; gelatinase B ; glutathione peroxidase ; glycemic effect ; Grifola frondosa ; interferon-alpha ; interleukin-6 ; kidneys ; malondialdehyde ; medicinal properties ; metformin ; mycelium ; oxidants ; oxidative stress ; polysaccharides ; rats ; reactive oxygen species ; superoxide dismutase ; transcription factor NF-kappa B ; tumor necrosis factor-alpha ; urea nitrogen
Language	English
Dates of publication	2019-01
Size	p. 310-322.
Publishing place	Springer US
Document type	Article
ZDB-ID	392344-7
ISSN	0273-2289
ISSN	0273-2289
DOI	10.1007/s12010-018-2803-6
Database	NAL-Catalogue (AGRICOLA)

In stock of ZB MED Bonn / Germany

Z 80/718: Show issues

Order via subito

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Details ▾
- See ZB MED holdings
- Order with fees

Article: [Effects of docosahexaenoic acid on hypoxia-induced pulmonary arterial hypertension].

Chen, Rui / Liu, Peijing / Yan, Jinchuan / Gu, Yuchun

Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chinese journal of tuberculosis and respiratory diseases

2014 Volume 37, Issue 2, Page(s) 109–112

Abstract: Objective: To investigate the effects of docosahexaenoic acid (DHA) on hypoxia-induced pulmonary arterial hypertension(PAH) and the mechanism.: Methods: PAH was induced by chronic intermittent hypoxia for 21 days in vivo. Forty male Sprague-Dawley ... ...

Abstract	Objective: To investigate the effects of docosahexaenoic acid (DHA) on hypoxia-induced pulmonary arterial hypertension(PAH) and the mechanism. Methods: PAH was induced by chronic intermittent hypoxia for 21 days in vivo. Forty male Sprague-Dawley rats were randomly divided into 4 groups (n = 10, each):a normal control group, DHA-treated groups in normoxia and hypoxia, and a PAH group. At the end of study, mean pulmonary arterial pressure (mPAP), right ventricular hypertrophy and the index of wall thickness of small pulmonary artery (WT% and WA%) among groups were compared. The changes of pulmonary arterial smooth muscle cell (PASMC) proliferation were determined by MTT in vitro. Migration assay was performed using the Boyden chamber. Real-time quantitative PCR was performed to quantify mRNA levels of the smooth muscle cell phenotype markers SM-α-actin, calponin and SM 22α under normoxic or hypoxic conditions, in the absence or presence of DHA. Results: DHA treatment significantly lowered mPAP [(22.7 ± 1.8) mmHg (1 mmHg = 0.133 kPa)], reduced thickening of small pulmonary artery wall [WT%:(21.6 ± 4.1)%, WA%: (52.0 ± 2.9)% ] and alleviated ventricular hypertrophy (34.2 ± 2.2) % compared to those of the hypoxic group (P < 0.05). DHA inhibited the proliferation, migration and phenotype switching of PASMCs induced by hypoxia in vitro. Conclusion: DHA therapy reduced mPAP in a rat model of hypoxia-induced PAH and this effect was linked with inhibition of pulmonary vascular remodelling.
MeSH term(s)	Actins/genetics ; Actins/metabolism ; Animals ; Calcium-Binding Proteins/genetics ; Calcium-Binding Proteins/metabolism ; Cell Movement/drug effects ; Cell Proliferation/drug effects ; Cells, Cultured ; Disease Models, Animal ; Docosahexaenoic Acids/administration & dosage ; Docosahexaenoic Acids/pharmacology ; Familial Primary Pulmonary Hypertension ; Hypertension, Pulmonary/etiology ; Hypertension, Pulmonary/metabolism ; Hypertension, Pulmonary/prevention & control ; Hypoxia/complications ; Male ; Microfilament Proteins/genetics ; Microfilament Proteins/metabolism ; Myocytes, Smooth Muscle/drug effects ; Myocytes, Smooth Muscle/metabolism ; Pulmonary Artery/drug effects ; Pulmonary Artery/metabolism ; Pulmonary Artery/physiopathology ; RNA, Messenger/genetics ; RNA, Messenger/metabolism ; Random Allocation ; Rats ; Rats, Sprague-Dawley ; Real-Time Polymerase Chain Reaction ; Calponins
Chemical Substances	Actins ; Calcium-Binding Proteins ; Microfilament Proteins ; RNA, Messenger ; smooth muscle actin, rat ; Docosahexaenoic Acids (25167-62-8)
Language	Chinese
Publishing date	2014-04-19
Publishing country	China
Document type	Journal Article ; Research Support, Non-U.S. Gov't
ZDB-ID	1027965-9
ISSN	1001-0939
ISSN	1001-0939
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.B 2465: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article: [Nuclear factor-κB pathway mediates the effects of CD137 signaling on NFATc1 expression in mice vascular smooth muscle cells].

Yin, Yunjie / Yan, Jinchuan / Wang, Zhongqun / Liu, Peijing / Liang, Yi

Zhonghua xin xue guan bing za zhi

2015 Volume 43, Issue 7, Page(s) 614–618

Abstract: Objective: To observe whether CD137 signaling could affect the nuclear factor of activated T cells c1 (NFATc1) expression through nuclear factor-κB (NF-κB) pathway in mice aortic vascular smooth muscle cells (VSMCs).: Methods: Adherence methods for ... ...

Abstract	Objective: To observe whether CD137 signaling could affect the nuclear factor of activated T cells c1 (NFATc1) expression through nuclear factor-κB (NF-κB) pathway in mice aortic vascular smooth muscle cells (VSMCs). Methods: Adherence methods for tissues explants were used for primary culture of mouse aortic VSMCs. The mRNA expression of CD137 and NFATc1 was detected by real-time quantitative PCR (RT-qPCR). The VSMCs protein expression of IκB-α, NF-κB p65, phospo-p65 and NFATc1 was determined by Western blot. The level of CD137 was measured by Flow Cytometry (FCM). Results: (1) The mRNA and protein expression of CD137 in VSMCs was significantly upregulated at 24 h after co-culture with TNF-α (10 ng/ml, all P < 0.05). (2) Compared with the control group, the level of p-NF-κB p65 in cytoplasm and nucleus was significantly increased (8.34 ± 0.28 vs. 1, P < 0.05, and 2.64 ± 0.42 vs. 1, P < 0.05) while the level of IκB-α was reduced (1 vs. 2.70 ± 0.28, P < 0.05) after co-treatment with agonist-CD137 mAb, above effects were partly blocked by adding specific NF-κB inhibitor PDTC (30 µmol/L: 1.15 ± 0.14 vs. 8.34 ± 0.28, P < 0.05, and 2.09 ± 0.12 vs. 2.64 ± 0.42, P < 0.05, and 1.78 ± 0.74 vs. 1, P < 0.05). (3) The mRNA (2.07 ± 0.09 vs. 1, P < 0.05) and protein (1.75 ± 0.07 vs. 1, P < 0.05) expression of NFATc1 was significantly upregulated by agonist CD137mAb compared with the control group, and these effects could be reversed by PDTC (1.15 ± 0.07 vs. 2.07 ± 0.09, P < 0.05, and 0.90 ± 0.11 vs. 1.75 ± 0.07, P < 0.05). Conclusion: CD137 signaling could affect the NFATc1expression in VSMCs through NF-kappaB pathway.
MeSH term(s)	Animals ; Cells, Cultured ; I-kappa B Proteins ; Mice ; Muscle, Smooth, Vascular/metabolism ; Myocytes, Smooth Muscle ; NF-KappaB Inhibitor alpha ; NF-kappa B/metabolism ; NFATC Transcription Factors/metabolism ; RNA, Messenger ; Signal Transduction ; Tumor Necrosis Factor Receptor Superfamily, Member 9/metabolism ; Tumor Necrosis Factor-alpha ; Up-Regulation
Chemical Substances	I-kappa B Proteins ; NF-kappa B ; NFATC Transcription Factors ; Nfkbia protein, mouse ; RNA, Messenger ; Tumor Necrosis Factor Receptor Superfamily, Member 9 ; Tumor Necrosis Factor-alpha ; NF-KappaB Inhibitor alpha (139874-52-5)
Language	Chinese
Publishing date	2015-07
Publishing country	China
Document type	Journal Article
ZDB-ID	603425-1
ISSN	0253-3758
ISSN	0253-3758
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.B 2276: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Docosahexaenoic acid inhibits development of hypoxic pulmonary hypertension: in vitro and in vivo studies.

Yan, Jinchuan / Chen, Rui / Liu, Peijing / Gu, Yuchun

International journal of cardiology

2013 Volume 168, Issue 4, Page(s) 4111–4116

Abstract: Background: Hypoxic pulmonary hypertension (HPH) is initiated by acute hypoxic pulmonary vasoconstriction followed by vascular remodeling and right ventricular failure. Numerous studies have shown that long-term supplementation with docosahexaenoic acid ...

Abstract	Background: Hypoxic pulmonary hypertension (HPH) is initiated by acute hypoxic pulmonary vasoconstriction followed by vascular remodeling and right ventricular failure. Numerous studies have shown that long-term supplementation with docosahexaenoic acid (DHA) may have a role in preventing cardiovascular disease. However, the effects of DHA on HPH remain unclear. Extracellular signal-regulated kinase 1/2 (ERK1/2) is known to be involved in the proliferation and migration of various cell types. In this study, we determined the role of DHA in the prevention of HPH via the ERK1/2 signal pathway. Methods: Rats were intragastrically administered with saline or DHA (100 mg) daily before exposure to room air or chronic hypoxia (O(2) content was maintained at 10%) for 8 h a day for 3 weeks. At the end of study, we compared the right ventricular systolic pressure (RVSP), the weight ratio of right ventricular (RV) free wall to the left ventricular (LV) including the septum (S) free wall, the percent wall thickness (wt.%) of small pulmonary arteries and the area of α-smooth muscle actin (α-SMA)-positive pulmonary artery smooth muscle cells (PASMCs) in the pulmonary arteries among the rats. In vitro, the proliferation and migration of PASMCs were through an MTT assay and a Boyden chamber, respectively. The phenotype marker expression and ERK1/2 activation in the PASMCs were through real-time PCR and western blot analysis, respectively. Results: Under hypoxia, DHA treatment reduced the RVSP (20.41 mmHg ± 2.18 vs. 35.46 mmHg ± 3.21; P < 0.05), the weight ratio of RV free wall to left ventricular and septal free wall [RV/(LV + S)] (0.27 ± 0.03 vs. 0.38 ± 0.05; P < 0.05), wt.% (17.45 ± 1.58% vs. 59.65 ± 4.59%; P < 0.05) and the percentage of SMA-positive vessels (55.42 ± 5.18% vs. 84.71 ± 6.22%; P < 0.05) compared with those of the saline-treated rats. Hypoxia promoted the proliferation, migration and phenotype switching of PASMCs in vitro. However, DHA treatment suppressed the hypoxia-induced changes. Additionally, DHA attenuated the expression of hypoxia-activated ERK1/2 in the PASMCs. Conclusions: Our observations indicate that DHA may potentially prevent HPH.
MeSH term(s)	Animals ; Cells, Cultured ; Docosahexaenoic Acids/therapeutic use ; Hypertension, Pulmonary/metabolism ; Hypertension, Pulmonary/prevention & control ; Hypoxia/metabolism ; Hypoxia/prevention & control ; Male ; Random Allocation ; Rats ; Rats, Sprague-Dawley
Chemical Substances	Docosahexaenoic Acids (25167-62-8)
Language	English
Publishing date	2013-10-09
Publishing country	Netherlands
Document type	Journal Article ; Research Support, Non-U.S. Gov't
ZDB-ID	779519-1
ISSN	1874-1754 ; 0167-5273
ISSN (online)	1874-1754
ISSN	0167-5273
DOI	10.1016/j.ijcard.2013.07.073
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 1673: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

To top

More links

Kategorien

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

In stock of ZB MED Bonn / Germany

Order via subito

Inter-library loan at ZB MED

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito